Corpus Intelligence IC Memo — PAM SPECIALTY HOSPITAL OF STOUGHTON 2026-04-26 09:04 UTC
IC Memo — PAM SPECIALTY HOSPITAL OF STOUGHTON
Investment Committee Memorandum | MA | 88 beds | Grade D | EBITDA uplift $1.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PAM SPECIALTY HOSPITAL OF STOUGHTON

CCN 222002 | NORFOLK, MA | 88 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

PAM SPECIALTY HOSPITAL OF STOUGHTON is a 88-bed safety-net/medicaid heavy in NORFOLK, MA with $24.6M in net patient revenue and a -15.3% operating margin. The hospital serves a payer mix of 17.4% Medicare, 53.4% Medicaid, and 29.2% commercial.

Thesis: Turnaround. Our ML models identify $1.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.3% to -7.9% (+736bps).

Net Revenue HCRIS$24.6M
Current EBITDA COMPUTED$-3.8M
Operating Margin COMPUTED-15.3%
Occupancy HCRIS58.5%
Revenue / Bed COMPUTED$280K
Net-to-Gross HCRIS37.7%
Distress Probability ML60.1%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
49
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -15.3% places it below the state median. Among 49 size-comparable peers (44-176 beds), the median margin is -9.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (44-176), prioritizing same-state peers. 49 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PAM SPECIALTY HOSPITAL OF STOU (Target)MA88$24.6M-15.3%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
STEWARD ST. ANNES HOSPITALMA175$322.3M12.8%
FAULKNER HOSPITALMA147$316.6M-7.9%
EMERSON HOSPITALMA111$315.1M-10.1%
BROCKTON HOSPITAL INC.MA175$305.2M-18.4%
THE MERCY HOSPITALMA150$276.4M-12.5%
MILFORD REGIONAL MEDICAL CENTEMA148$254.6M-7.2%
COOLEY DICKINSON HOSPITALMA118$233.6M2.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$517K+210bp18mo
Cost to Collect4.5%2.5%$492K+200bp12mo
Denial Rate Reduction12.0%6.5%$487K+198bp12mo
A/R Days Reduction5200.0%3800.0%$299K+122bp9mo
Clean Claim Rate88.0%96.0%$16K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$517K
Cost to Collect
$492K
Denial Rate Reduction
$487K
A/R Days Reduction
$299K
Clean Claim Rate
$16K
Total EBITDA Uplift$1.8M
Current EBITDA$-3.8M
+ RCM Uplift+$1.8M
Pro Forma EBITDA$-1.9M
Current Margin-15.3%
Pro Forma Margin-7.9%
WC Released (1x)$944K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-5.8M$-6.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-5.8M$-9.2M0.00x-100.0%
Bull Case9.0x11.0x$-5.2M$-5.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-5.2M$-7.1M0.00x-100.0%
Bear Case11.0x10.0x$-6.4M$-13.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-6.4M$-17.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (53.4%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 60.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 49 hospitals with 44-176 beds
  • Same-state prioritization (n=50)
  • Comp margins: P25=-18.0% / P50=-9.0% / P75=2.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.